An Open-label Extension Study To Evaluate Safety Of PF-06252616 in Boys With Duchenne Muscular Dystrophy

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys With Duchenne Muscular Dystrophy

Category & Conditions:
Rare Diseases
Medicine:
Domagrozumab (PF-06252616)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B5161004
Open Plain Language Summary Result:Click here